CTLA4 and mesothelioma: To this end, in this study, we investigated this molecule in a cohort of mesothelioma patients treated with the anti-CTLA-4 mAb tremelimumab combined with the anti-PD-L1 mAb durvalumab, within the NIBIT-MESO-1 trial (NCT02588131).